Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Sep 26, 2020; 8(18): 4022-4033
Published online Sep 26, 2020. doi: 10.12998/wjcc.v8.i18.4022
Table 4 Adverse events of each regimen
Adverse eventsGemcitabine mono, n = 45GA, n = 34FOLFIRINOX, n = 25P value
Admission13 (28.9)11 (32.4)10 (40.0)0.359
Thromboembolism4 (8.9)2 (5.9)7 (28.0)0.041a
Neuropathy (Grade 1,2/3,4)0 (0.0) (0/0)21 (61.8) (7/14)7 (28.0) (6/1)0.006a
Neutropenia (Grade 1,2/3,4)18 (40.0) (9/9)26 (76.5) (9/17)21 (84.0) (7/14)0.000a
Thrombocytopenia (Grade 1,2/3,4)24 (53.3) (14/10)16 (47.0) (10/6)7 (28.0) (1/6)0.241
Nausea (Grade 1,2/3,4)12 (26.6) (11/1)7 (21.6) (5/2)9 (36.0) (7/2)0.344
Fatigue (Grade 1,2/3,4)22 (48.9) (12/10)24 (64.7) (12/10)16 (64.0) (9/7)0.245
Diarrhea (Grade 1,2/3,4)8 (17.8) (7/1)7 (20.6) (5/2)8 (32.0) (4/4)0.065
Colitis/pneumonia9 (20.0) (2/7)7 (20.5) (1/6)6 (24.0) (3/3)0.959